BioMarin Pharmaceuticals Inc (BMRN) Valuation
Historical valuation analysis based on 500 data points (2024-09-23 to 2026-09-21)
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and o...
BioMarin Pharmaceuticals Inc (BMRN) currently trades at a P/E ratio of 47.12 (historical range: 15.74–55.05, median: 26.51), placing it at the 93th percentile — expensive relative to its history, P/S ratio of 3.91 (range: 3.03–5.46, 60th percentile — above its historical average), EV/EBITDA of 37.66 (range: 28.63–41.53, 76th percentile).
BioMarin Pharmaceuticals Inc trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 47.12 | 15.74 | 26.51 | 55.05 | 93th | expensive relative to its history |
| P/S Ratio | 3.91 | 3.03 | 3.78 | 5.46 | 60th | above its historical average |
| EV/EBITDA | 37.66 | 28.63 | 33.65 | 41.53 | 76th | above its historical average |
| FCF Yield | 0.06 | 0.02 | 0.06 | 0.08 | 47th | near its historical average |
BioMarin Pharmaceuticals Inc (BMRN) Valuation & P/E History
BioMarin Pharmaceuticals Inc (BMRN) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry currently trading at $63.80 with a market capitalization of $12.3 billion. This page provides historical valuation analysis for BMRN based on 500 data points covering 2024-09-23 to 2026-09-21. The P/E ratio of 47.12 is above the historical median of 26.51, placing BMRN at the 93th percentile of its valuation range. The P/S ratio of 3.91 compares to a median of 3.78.
BMRN Valuation Metrics & Historical Range
The valuation table above shows BioMarin Pharmaceuticals Inc's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether BMRN is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests BMRN is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for BioMarin Pharmaceuticals Inc.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is BMRN Overvalued or Undervalued?
BioMarin Pharmaceuticals Inc trades well above its own historical valuation range across most metrics. The overall valuation percentile of 76 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive BMRN is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full BMRN analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.BMRN trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.